These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29714562)

  • 1. FDA Expectations for Demonstrating Interchangeability.
    Chance K
    Ther Innov Regul Sci; 2018 May; 52(3):369-373. PubMed ID: 29714562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
    O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
    Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interchangeability Of Biological Drug Products-FDA Draft Guidance.
    Endrenyi L; Markus R
    J Biopharm Stat; 2019; 29(6):1003-1010. PubMed ID: 31023141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sowing confusion in the field: the interchangeable use of biosimilar terminology.
    McKinley L; Kelton JM; Popovian R
    Curr Med Res Opin; 2019 Apr; 35(4):619-621. PubMed ID: 30556742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable.
    Afzali A; Furtner D; Melsheimer R; Molloy PJ
    Adv Ther; 2021 May; 38(5):2077-2093. PubMed ID: 33745111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Science of Biosimilars-Updating Interchangeability.
    Cavazzoni P; Yim S
    JAMA; 2024 Oct; 332(15):1235-1236. PubMed ID: 39292484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacist Substitution of Biological Products: Issues and Considerations.
    Li E; Ramanan S; Green L
    J Manag Care Spec Pharm; 2015 Jul; 21(7):532-9. PubMed ID: 26108377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar names for similar biologics.
    Casadevall N; Felix T; Strober BE; Warnock DG
    BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution.
    Druedahl LC; Kälvemark Sporrong S; Minssen T; Hoogland H; De Bruin ML; van de Weert M; Almarsdóttir AB
    PLoS One; 2022; 17(1):e0262537. PubMed ID: 35015783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?
    Alvarez DF; Wolbink G; Cronenberger C; Orazem J; Kay J
    BioDrugs; 2020 Dec; 34(6):723-732. PubMed ID: 32990892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B; Zuñiga L
    BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The complexities of biosimilars and the regulatory approval process.
    Lucio S
    Am J Manag Care; 2018 Jun; 24(11 Suppl):S231-S236. PubMed ID: 29957908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustainable Integration of US Food and Drug Administration-Approved Biosimilars: Pharmacy- Versus Physician-Driven Change.
    Waterhouse DM; Ward P; Drosick DR; Burdette C; Davies D; Mendenhall MA
    JCO Oncol Pract; 2023 Nov; 19(11):1053-1057. PubMed ID: 37738533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding State Regulation of Biosimilars and Effect on Prescribers.
    Yale K; Awosika O; Rengifo-Pardo M; Ehrlich A
    J Drugs Dermatol; 2017 Oct; 16(10):995-1000. PubMed ID: 29036253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars in the United States: Emerging Issues in Litigation.
    Wong AY; Rumore MM; Chan AW
    BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilar safety factors in clinical practice.
    Reinisch W; Smolen J
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The constrained prescription, interchangeability and substitution of biosimilars.
    Minghetti P; Rocco P; Schellekens H
    Nat Biotechnol; 2015 Jul; 33(7):688-9. PubMed ID: 26154003
    [No Abstract]   [Full Text] [Related]  

  • 19. Biosimilars: The US Regulatory Framework.
    Christl LA; Woodcock J; Kozlowski S
    Annu Rev Med; 2017 Jan; 68():243-254. PubMed ID: 27813877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing biosimilarity and interchangeability of biosimilar products.
    Chow SC
    Stat Med; 2013 Feb; 32(3):361-3. PubMed ID: 23307569
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.